Disclosures for "Efficacy and Safety of Crisugabalin in Patients With Moderate-to-Severe Central Neuropathic Pain: A Phase 3 Randomized Clinical Trial"
-
Author has nothing to disclose
-
Author has nothing to disclose
-
Author has nothing to disclose
-
Author has nothing to disclose
-
Author has nothing to disclose
-
Author has nothing to disclose
-
Author has nothing to disclose
-
Author has nothing to disclose
-
Author has nothing to disclose
-
Dr. Pan has received personal compensation for serving as an employee of Haisco Pharmaceutical Group Co., Ltd..
-
Author has nothing to disclose